Eli Lilly launches Foundayo pill in UK
Eli Lilly has launched its oral weight-loss drug Foundayo in the UK for private prescription use. The treatment becomes the first oral GLP-1 option available in Europe. Health officials are reviewing the pill for NHS access.
Xurve View
Insights:
Xurve View
ELI LILLY & CO has launched its oral weight-loss drug Foundayo in the United Kingdom, pricing monthly doses between £100 and £120. The rollout makes Britain the first European country where the oral treatment is available. The launch precedes state health coverage decisions as competitors vie for market share.
